Locking in an early pharma deal only benefits companies which are worried about their R&D risk, and they pay a larger risk premium to the licensee accordingly. By electing to take on all the R&D risk themselves (all of their actions to date suggest this is the strategy), I think they are setting themselves up for a distribution only deal with royalties greater than 50%+. The previous analyst reports have all assumed 15-20% royalties as a conservative estimate. Royalties are such a big chunk of the pie that the difference between 50% and 15% is going to have an almost linear impact on future revenues and in turn the SP.
It's an extra gamble but given their unique risk/reward situation, it's definitely a +EV move if big pharma are only willing to offer a deal based on the industry average.
- Forums
- ASX - By Stock
- A parallel with SRX
Locking in an early pharma deal only benefits companies which...
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.20M |
Open | High | Low | Value | Volume |
23.0¢ | 23.5¢ | 23.0¢ | $74.06K | 320.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 102830 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.0¢ | 703 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 97830 | 0.230 |
8 | 99772 | 0.225 |
14 | 118171 | 0.220 |
3 | 48958 | 0.215 |
6 | 91017 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.240 | 703 | 1 |
0.245 | 20000 | 1 |
0.250 | 57573 | 3 |
0.255 | 29564 | 3 |
0.260 | 33915 | 5 |
Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |